Company / Operating Income
CRISPR Therapeutics AG Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$664.6M
FY2025
5-year range
-$673.2M / $373.5M
FY2021-FY2025
Trend
-42.4%
vs FY2024
Sector context
#193 of 204
Health Care
What the data says
Among 204 Health Care companies, CRISPR Therapeutics AG is in the bottom 5% for operating income. Operating Income has fluctuated over the past 10 years, ranging from -$673M in FY2022 to $374M in FY2021.
Based on SEC 10-K filings.
-$665M in FY2025.
Declined from -$223M to -$665M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 204This company -$664.6M Sector average $107.7M
▼
-716.9% below sector average
Key checks
Key Insights
- In FY2025, operating income decreased 42.4% year-over-year.
- Ranks #193 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2021.
- Lowest operating income in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$664.6M | -42.4% |
| FY2024 | -$466.6M | -109.7% |
| FY2023 | -$222.5M | +66.9% |
| FY2022 | -$673.2M | -280.2% |
| FY2021 | $373.5M | +205.4% |
| FY2020 | -$354.4M | -858.3% |
| FY2019 | $46.7M | +168.6% |
| FY2018 | -$68.1M | -164.8% |
| FY2017 | -$25.7M | -288.2% |
| FY2016 | -$6.6M | +74.2% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026